Aligos Therapeutics Stock Forecast
NASDAQ: ALGSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ALGS analyst consensus
Consensus (8 analysts)
none
Avg. price target
$52.38+886.44%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Aligos Therapeutics (2026-10-09), 8 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $52.38, with a high estimate of $175.00 and a low estimate of $20.00. The average target implies upside of 886.4% from the current price of $5.31.
The spread between the highest and lowest targets is 775.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALGS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 13% |
| Buy | 7 | 88% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | +276.65% |
| Average target | $52.38 | +886.44% |
| High target | $175.00 | +3195.67% |